Literature DB >> 18957671

Prostate-specific antigen: a misused and maligned prostate cancer biomarker.

Ian M Thompson, Catherine M Tangen, Alan R Kristal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18957671      PMCID： PMC2579315          DOI： 10.1093/jnci/djn368

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  8 in total

1.  Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Authors:  Ian M Thompson; Donna Pauler Ankerst; Chen Chi; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Ziding Feng; Howard L Parnes; Charles A Coltman
Journal:  J Natl Cancer Inst       Date:  2006-04-19       Impact factor: 13.506

2.  Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs.

Authors:  Bruce M Psaty; Thomas Lumley
Journal:  JAMA       Date:  2008-03-26       Impact factor: 56.272

3.  Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase.

Authors:  Alan R Kristal; Chen Chi; Catherine M Tangen; Phyllis J Goodman; Ruth Etzioni; Ian M Thompson
Journal:  Cancer       Date:  2006-01-15       Impact factor: 6.860

Review 4.  Surrogate end points in clinical trials: are we being misled?

Authors:  T R Fleming; D L DeMets
Journal:  Ann Intern Med       Date:  1996-10-01       Impact factor: 25.391

5.  Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.

Authors:  Ian M Thompson; Donna Pauler Ankerst; Chen Chi; M Scott Lucia; Phyllis J Goodman; John J Crowley; Howard L Parnes; Charles A Coltman
Journal:  JAMA       Date:  2005-07-06       Impact factor: 56.272

6.  Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.

Authors:  Ian M Thompson; Chen Chi; Donna Pauler Ankerst; Phyllis J Goodman; Catherine M Tangen; Scott M Lippman; M Scott Lucia; Howard L Parnes; Charles A Coltman
Journal:  J Natl Cancer Inst       Date:  2006-08-16       Impact factor: 13.506

7.  Problems of spectrum and bias in evaluating the efficacy of diagnostic tests.

Authors:  D F Ransohoff; A R Feinstein
Journal:  N Engl J Med       Date:  1978-10-26       Impact factor: 91.245

Review 8.  Obesity and prostate cancer mortality.

Authors:  Alan R Kristal; Zhihong Gong
Journal:  Future Oncol       Date:  2007-10       Impact factor: 3.404
  8 in total
  5 in total

1.  The effect of lowering cholesterol through diet on serum prostate-specific antigen levels: A secondary analysis of clinical trials.

Authors:  Viranda H Jayalath; Katherine Lajkosz; Neil E Fleshner; Robert J Hamilton; David J A Jenkins
Journal:  Can Urol Assoc J       Date:  2022-08       Impact factor: 2.052

Review 2.  Effective incorporation of biomarkers into phase II trials.

Authors:  Lisa M McShane; Sally Hunsberger; Alex A Adjei
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

3.  The C-terminal fragment of prostate-specific antigen, a 2331 Da peptide, as a new urinary pathognomonic biomarker candidate for diagnosing prostate cancer.

Authors:  Kenji Nakayama; Takahiro Inoue; Sadanori Sekiya; Naoki Terada; Yu Miyazaki; Takayuki Goto; Shigeki Kajihara; Shin-Ichiro Kawabata; Shinichi Iwamoto; Kuniko Ikawa; Junko Oosaga; Hiroaki Tsuji; Koichi Tanaka; Osamu Ogawa
Journal:  PLoS One       Date:  2014-09-18       Impact factor: 3.240

4.  The Relationship Between Metformin and Serum Prostate-Specific Antigen Levels.

Authors:  Viranda H Jayalath; Christopher Ireland; Neil E Fleshner; Robert J Hamilton; David J A Jenkins
Journal:  Prostate       Date:  2016-07-12       Impact factor: 4.104

5.  Prostate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine Design.

Authors:  Bently P Doonan; Azizul Haque
Journal:  J Clin Cell Immunol       Date:  2015-08-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.